AN2 Therapeutics, Inc. (ANTX)
| Previous Close | 1.0800 |
| Open | 1.0700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.0600 - 1.1000 |
| 52 Week Range | 0.8700 - 22.2200 |
| Volume | |
| Avg. Volume | 611,985 |
| Market Cap | 32.528M |
| Beta (5Y Monthly) | -0.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1800 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.33 |
Business WireAN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
MENLO PARK, Calif., October 17, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company has received a second year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel, boron containing small molecules for the treatment of tuberculosis (TB) and malaria.
Business WireAN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
MENLO PARK, Calif., August 28, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the H.C. Wainwright 26th Annual Global Investment Conference.
